Dermata Therapeutics Inc (DRMA) FinancialsDRMADermata Therapeutics Inc

Evaluating the bottom line, Dermata Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -183.89%, provide a clear picture of how effectively DRMA converts its operational activities into shareholder value.

In the context of the broader market, DRMA competes directly with industry leaders such as PULM and KAPA. With a market capitalization of $6.64M, it holds a leading position in the sector. When comparing efficiency, DRMA's gross margin of N/A stands against PULM's N/A and KAPA's N/A. Such benchmarking helps identify whether Dermata Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Dermata has shown increasing losses, with a net loss of $2.97 million in Q2 2026, and a GAAP EPS of -$0.74. The company has a negative forward P/E ratio, indicating no expected profitability in the near term.